StockWatch: Gene Editing Shares Jump on ESGCT Data, FDA Draft Guidance
Shares of gene editing therapy companies mostly surged this past week on two growth catalysts: Data readouts at the European Society of Gene and Cell Therapy’s 33rd ESGCT Annual Congress, and the FDA's new draft guidance for personalized gene therapies.